for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Brickell Biotech Inc

BBI.OQ

Latest Trade

1.17USD

Change

0.01(+0.86%)

Volume

363,738

Today's Range

1.01

 - 

1.18

52 Week Range

0.47

 - 

2.64

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.16
Open
1.14
Volume
363,738
3M AVG Volume
81.59
Today's High
1.18
Today's Low
1.01
52 Week High
2.64
52 Week Low
0.47
Shares Out (MIL)
53.52
Market Cap (MIL)
62.61
Forward P/E
-1.65
Dividend (Yield %)
--

Next Event

Q4 2020 Brickell Biotech Inc Earnings Release

Latest Developments

More

Brickell Biotech Inc - R. Michael Carruthers, CFO And Principal Accounting Officer, Will Be Resigning

Brickell Biotech Inc - Kaken Plans To Launch ECCLOCK For Treatment Of Primary Axillary Hyperhidrosis In Japan On November 26, 2020

Brickell Biotech Reports Q3 Revenue Of $100,000

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Brickell Biotech Inc

Brickell Biotech, Inc., formerly Vical Incorporated, is a clinical-stage pharmaceutical company that focuses on the development of therapeutics for the treatment of skin diseases. The Company’s pipeline consists of molecular entities targeting the treatment of the indications, such as hyperhidrosis, cutaneous T-cell lymphoma, allergic contact dermatitis, psoriasis and androgenic alopecia. The Company’s product candidates include BBI-3000, BBI-6000 and Sofpironium Bromide. Sofpironium Bromide is a topical soft anticholinergic for axillary hyperhidrosis. BBI-3000 is an oral rexinoid for cutaneous T-cell lymphoma. BBI-6000 is a retinoic acid-related orphan nuclear receptor gamma antagonist, which is develops for psoriasis.

Industry

Biotechnology & Drugs

Contact Info

5777 Central Ave Ste 102

BOULDER, CO

80301-2870

United States

+1.720.5054755

https://brickellbio.com/

Executive Leadership

Reginald L. Hardy

Chairman of the Board, Co-Founder

Robert B. Brown

Chief Executive Officer, Director

Andrew D. Sklawer

Co-Founder, Chief Operating Officer, Secretary

Albert N. Marchio

Chief Financial Officer

Jose Breton

Chief Accounting Officer, Controller

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2020(E)

0.0K
EPS (USD)

2017

-7.070

2018

-5.180

2019

-4.500

2020(E)

-0.710
Price To Earnings (TTM)
--
Price To Sales (TTM)
25.41
Price To Book (MRQ)
1.95
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
2.34
LT Debt To Equity (MRQ)
0.91
Return on Investment (TTM)
-113.66
Return on Equity (TTM)
-84.50

Latest News

Latest News

BRIEF-Brickell Biotech Announces Positive Phase 3 Pivotal Study Results For Sofpironium Bromide In Japan

* BRICKELL BIOTECH ANNOUNCES POSITIVE PHASE 3 PIVOTAL STUDY RESULTS FOR SOFPIRONIUM BROMIDE IN JAPAN RELEASED BY DEVELOPMENT PARTNER, KAKEN PHARMACEUTICAL

BRIEF-Brickell Biotech Offers 15.2 Mln Shares Of Common Stock

* BRICKELL BIOTECH - OFFERING 15.2 MILLION SHARES OF COMMON STOCK & COMMON WARRANTS TO PURCHASE 7.6 MILLION SHARES OF CO'S COMMON STOCK Source text: (https://bit.ly/2ATpRpi) Further company coverage:

BRIEF-Brickell Biotech Posts Quarterly Loss Per Share $0.45

* BRICKELL BIOTECH REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Brickell Biotech Files Prospectus Relating To Resale Of Up To 2.6 Mln Shares By Lincoln Park Capital

* BRICKELL BIOTECH INC FILES PROSPECTUS RELATES TO RESALE, FROM TIME TO TIME, OF UP TO 2.6 MILLION SHARES OF COMMON STOCK BY LINCOLN PARK CAPITAL FUND, LLC Source text: (https://bit.ly/3bAM0Gt) Further company coverage:

BRIEF-Brickell Biotech Filed Amendment No. 1 To Definitive Proxy Statement

* BRICKELL BIOTECH INC - FILED AMENDMENT NO. 1 TO DEFINITIVE PROXY STATEMENT FILED BY CO ON MARCH 30

BRIEF-Brickell Biotech Issues Prospectus Related To Resale Of Common Stock By Lincoln Park Capital Fund, Llc

* BRICKELL BIOTECH - PROSPECTUS RELATES TO RESALE, FROM TIME TO TIME, OF UP TO 2.6 MILLION SHARES OF COMMON STOCK BY LINCOLN PARK CAPITAL FUND, LLC Source text: https://bit.ly/3aI2fkK Further company coverage:

BRIEF-Brickell Biotech Q4 Revenue $700,000 Versus $2.5 Million

* BRICKELL BIOTECH REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Brickell Biotech Files Prospectus Relates To Offer, Sale By Selling Stockholder Of Up To 1.6 Million Shares

* BRICKELL BIOTECH FILES PROSPECTUS RELATES TO OFFER, SALE FROM TIME TO TIME BY SELLING STOCKHOLDER OF UP TO 1.6 MILLION SHARES OF CO'S COMMON STOCK Source: (https://bit.ly/2PzRf0i) Further company coverage:

BRIEF-Lincoln Park Capital Fund Llc Reports 9.99% Passive Stake In Brickell Biotech

* LINCOLN PARK CAPITAL FUND LLC REPORTS 9.99% PASSIVE STAKE IN BRICKELL BIOTECH INC AS OF FEBRUARY 20, 2020 - SEC FILING Source text : (http://bit.ly/3a8REOV) Further company coverage:

BRIEF-Brickell Biotech Announces Settlement Of Dispute With Bodor Labs And Entry Into Equity Funding Agreements

* BRICKELL BIOTECH ANNOUNCES SETTLEMENT OF DISPUTE WITH BODOR LABS AND ENTRY INTO EQUITY FUNDING AGREEMENTS

BRIEF-Brickell Biotech Inc Files For Mixed Shelf Of Up To $75 Million

* BRICKELL BIOTECH INC FILES FOR MIXED SHELF OF UP TO $75 MILLION – SEC FILING Source text: (https://bit.ly/38h14r9) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up